anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The Center for Medicare and Medicaid Services requires Organ Procurement Organizations (OPOs) to verify and document that any potential organ donor has been pronounced dead per applicable legal requirements of local, state, and federal laws. However, OPO practices regarding death by neurologic criteria (DNC) verification are not standardized, and little is known about their DNC verification processes. This study aimed to explore OPO practices regarding DNC verification in the United States.
METHODS: An electronic survey was sent to all 57 OPOs in the United States from June to September 2023 to assess verification of policies and practices versus guidelines, concerns about policies and practices, processes to address concerns about DNC determination, and communication practices.
RESULTS: Representatives from 12 OPOs across six US regions completed the entire survey; 8 of 12 reported serving > 50 referral hospitals. Most respondents (11 of 12) reported comparing their referral hospital's DNC policies with the 2010 American Academy of Neurology Practice Parameter and/or other (4 of 12) guidelines. Additionally, most (10 of 12) reported independently reviewing and verifying each DNC determination. Nearly half (5 of 12) reported concerns about guideline-discordant hospital policies, and only 3 of 12 thought all referral hospitals followed the 2010 American Academy of Neurology Practice Parameter in practice. Moreover, 9 of 12 reported concerns about clinician knowledge surrounding DNC determination, and most (10 of 12) reported having received referrals for patients whose DNC declaration was ultimately reversed. All reported experiences in which their OPO requested additional assessments (11 of 12 clinical evaluation, 10 of 12 ancillary testing, 9 of 12 apnea testing) because of concerns about DNC determination validity.
CONCLUSIONS: Accurate DNC determination is important to maintain public trust. Nearly all OPO respondents reported a process to verify hospital DNC policies and practices with medical society guidelines. Many reported concerns about clinician knowledge surrounding DNC determination and guideline-discordant policies and practices. Educational and regulatory advocacy efforts are needed to facilitate systematic implementation of guideline-concordant practices across the country.
All sedated and ventilated critically ill patients will be exposed to the Masimo Sedline® sensor. Its pEEG scores, including the PSI, will be registered by the patient primary nurse every 4 hours for the first 5 days of ventilation. At the same time, CBS will be evaluated by a specialized PICU nurse and by a critical-care expert physician, blinded to each other. In case of chemically paralyzed patients, a paralysis holiday will be performed when clinically possible . A CBS will be assessed when the paralytic agents will be considered washed out. The patient's analgosedation strategy and analgosedation protocol will not be standardized but will be decided by the treating physician based on the international recommendations.
The invention provides a fiber reinforced polymer denture gasket material and a preparation method thereof. Generally, when the denture is worn, a denture gasket is arranged between the denture and the dental bed, so that the fit between the denture and the dental bed can be improved, the pressure during chewing can be buffered, and the comfort level of a wearer can be improved. The oral environment is an environment with oxygen in the daytime and without oxygen at night, and saliva and food residues are possibly in the meantime. The denture pad has high requirements on the water absorption and saliva resistance of the material in such an environment. The denture pad also needs to bear the pressure in the repeated chewing process, and has higher requirement on the fatigue resistance of the material. The invention fully considers the using environment of the denture pad and the requirement on the material performance, and adds the fiber into the room temperature curing silicon rubber. The fiber reinforced polymer denture gasket material provided by the invention is simple and convenient in preparation method, and has the advantages of good elasticity, low breakage rate of the edge of the diaphragm, high tearing strength, good tensile property and the like, the elastic recovery rate reaches more than 99.6%, and the denture gasket prepared in practical application has excellent performance.
The use of glutamic acid (I) or related amino acids, or their derivs., metabolites or salts, for the oral treatment of hypertension is claimed. The dose is up to 30 g or more per day, esp. 3 4g doses initially and the 3 2g doses for maintenance. If required, (I) is administered together with a saliuretic, other antihypertensives or Mg, and provides blood pressure readings of 140 +/- 25 mm systolic and 70 +/- 20 mm diastolic. USE/ADVANTAGE - Since intravenous admin. of (I) is known to increase the blood level of adrenaline and other vasoconstrictors its use in hypertensive patients has been contraindicated. It is now found, however, that oral admin. of (I) reduces blood pressure, even in patients who do not respond to conventional treatments. (I) can cause mild sleep disturbance but this wears off after a week and in no cases has it been severe  enough to cause the treatment to be discontinued.
Wilson disease (hepatolenticular degeneration) is an autosomal recessive disorder of copper transport, resulting in copper accumulation and toxicity to the liver and brain. The gene (locus WND) has been mapped to chromosome 13 band q14.3. On three overlapping yeast artificial chromosomes (YACs) from this region, a sequence similar to the proposed copper binding motifs of the putative ATPase (MNK) defective in Menkes disease was identified. It was shown that this sequence forms part of a P-type ATPase gene (Wc1) that is very similar to MNK, with at least six putative metal binding domains homologous to those found in prokaryotic heavy metal transporters. This gene lies within a 300 kb region that has been identified as a likely location for WND. The gene is expressed in the liver and kidney and is a candidate for Wilson disease.
OBJECTIVE: To investigate whether curcumin alleviates septic lung injury by inhibiting ferroptosis through modulating the TXNIP/TRX-1/GPX4 pathway.
METHODS: Male C57BL/6 mice were randomly divided into Sham group, cecal ligation puncture (CLP)-induced sepsis group, CLP with curcumin treatment (50, 100, and 200 mg/kg) groups, and CLP with both curcumin (200 mg/kg) and TRX-1 inhibitor PX-12 (25 mg/kg) treatment group. Inflammatory factors, MDA, MPO, and GSH levels in the lung tissue of the mice were detected. Beas-2B cells stimulated with lipopolysaccharide (LPS; 1 μg/mL) were treated with 2.5, 5, or 10 μmol/L curcumin or with 10 μmol/L curcumin combined with 5 μmol/L PX-12, and the changes in MDA, Fe2+ and ROS levels were assessed. Western blotting was performed to detect the protein expressions of TXNIP, TRX-1, GPX4 and X-CT in both the mouse lung tissues and Beas-2B cells.
RESULTS: The mice with CLP-induced sepsis showed severe lung injury with elevated expressions of IL-6, IL-1β, TNF-α, MDA and MPO and decreased GSH expression. In Beas-2B cells, LPS stimulation significantly increased MDA and Fe2+ levels and ROS release, increased TXNIP protein expression, and lowered the protein expression levels of TRX-1, GPX4 and X-CT, and these changes were also observed in the septic mice. Curcumin treatments at different concentrations obviously alleviated lung injury in the septic mice and reduced LPS-induced injury in Beas-2B cells. Curcumin significantly decreased the release of inflammatory factors, MDA and MPO, increased GSH level, lowered Fe2+, MDA and ROS levels, increased TXNIP protein expression, and lowered the protein expressions of TRX-1, GPX4 and X-CT in both septic mouse lung tissues and LPS-stimulated Beas-2B cells. The protective effect of curcumin was effectively blocked by PX-12 treatment.
CONCLUSION: Curcumin inhibits ferroptosis and alleviates septic lung injury in mice by elevating TRX-1 and GPX4 and decreasing TXNIP in the lung tissue.
A device is disclosed for administering a drug at a controlled rate for a prolonged period of time to a drug receptor area to produce a nonsystemic or systemic physiological or pharmacological effect. The device is comprised of a hollow deformable member that is movable from a collapsed to an expanded position and returnable to a collapsed position after an extended period of time. A housing is attached to the deformable member and it is internally divided into a first and second chamber with the chambers separated by an impermeable, pressure responsive movable bladder. The first chamber contains a drug and it has a discharge port for releasing the drug to the exterior of the device. The second chamber contains a means for generating pressure that is applied against the bladder. Drug is released from the first chamber through the discharge port by the bladder moving in response to pressure generated in the second chamber to increase its volume while simultaneously reducing the volume of the first chamber to release the drug at a controlled rate over a prolonged period of time. The device is initially optionally contained in a bioerodible container that erodes in the area to release the container.
In the Parent Study, Patients will be assessed during three study phases: a baseline period, a 6-week treatment period, and a 6-week post-treatment washout period. If within 6 weeks prior to the initial screening visit, a patient has received any of the prohibited medications defined in the eligibility criteria (irrespective of the preceding treatment duration) a wash-out study-run in of 6 weeks is required prior to the first baseline assessment. All patients will receive the study drug during the treatment period. For each individual patient, the Parent Study lasts for approximately 3.5 - 4 months during which there are 6 visits to the study site.

This Extension Phase allows patients who have completed the Parent Study to, at the discretion of the Principal Investigator (PI), continue treatment with N-Acetyl-L-Leucine (IB1001). Patients will receive treatment with IB1001 for two one-year treatment periods, separated by a 6-week washout. All patients will receive the study drug during the two one-year treatment periods. For each individual patient, the Extension Phase lasts for approximately 25.5 months, during which there are 6 visits to the study site.
Patients in Stage IV Arm VIII receive the UH-3 regimen as in STAGE III FHWT (UPFRONT BIOPSY/DELAYED NEPHRECTOMY) Arm II above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.
Neutrophil granulocytes are important components of the innate immune system and pioneers in the fight against both fungal and bacterial infections. If pathogens enter the body, they are marked as foreign by antibodies and the complement system. Afterwards receptors on the neutrophils recognize and bind on these foreign substances to make them harmless. This process is called phagocytosis. Hepatitis C virus (HCV) and neutrophils are rarely associated. The HCV belongs to the Flaviviridae. It is a single-stranded, enveloped RNA virus with a positive polarity, which cause chronic hepatitis C (CHC) in approximately 170 million people worldwide. Subsequently, such an infection leads to liver cirrhosis and carcinoma in a significant proportion of patients. The virus infects mainly hepatocytes, but extrahepatic replication has also been shown. HCV usually enters the cell through receptor-mediated endocytosis (claudin-1, cluster of differentiation (CD)81, occludin and scavenger receptor 1), before it abuses the cell's own infrastructure for the viral protein synthesis.

The aim of this study is to determine neutrophil function in chronic hepatitis C infected patients. Furthermore the investigators want to examine if neutrophils or their precursor cells are infected with HCV and if this leads to their dysfunction.
Colorectal cancer (CRC) is a significant global health concern. Prognostication of CRC traditionally relies on the Union for International Cancer Control (UICC) and American Joint Committee on Cancer (AJCC) TNM staging classifications, yet clinical outcomes often vary independently of stage. Despite similarities, rectal and colon cancers are distinct in their diagnostic methodologies and treatments, with MRI and CT scans primarily used for staging rectal and colon cancers, respectively. This paper examines the challenges in accurately assessing prognostic factors of colon cancer such as primary tumor extramural extension, retroperitoneal surgical margin (RSM) involvement, extramural vessel invasion (EMVI), and lymph node metastases through preoperative CT and MRI. It highlights the importance of these factors in risk stratification, treatment decisions, and surgical planning for colon cancer patients. Advancements in imaging techniques are crucial for improving clinical management and optimizing patient outcomes, underscoring the necessity for ongoing research to refine diagnostic methods and incorporate novel findings into practice.
Place the adhesive side of Vivelle-Dot on a clean, dry area of the trunk of the body (including the abdomen or buttocks). Do not apply Vivelle-Dot to the breasts.

Replace Vivelle-Dot twice weekly. Rotate the sites of application, with an interval of at least 1 week allowed between applications to a particular site. Select an area that is not oily, damaged, or irritated. Avoid the waistline, since tight clothing may rub the system off. Apply the system immediately after opening the pouch and removing the protective liner. Press the system firmly in place with the palm of the hand for about 10 seconds, making sure there is good contact, especially around the edges.

In the event that a system falls off, reapply the same system or apply a new system to another location. In either case, continue the original treatment schedule. If a woman has forgotten to apply Vivelle-Dot, have her apply a new system as soon as possible. Apply the new system on the original treatment schedule. The interruption of treatment in women taking Vivelle-Dot might increase the likelihood of breakthrough bleeding, spotting and recurrence of symptoms.
Dosing based on American Academy of Pediatrics (AAP), American Academy Society for Parenteral and Enteral Nutrition (ASPEN), European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN)/ European Society for Parenteral and Enteral Nutrition (ESPEN)/ European Society of Paediatric Research (ESPR)/ Chinese Society for Parenteral and Enteral Nutrition (CSPEN) guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
Peripheral arterial disease (PAD) is associated with lower-extremity muscle wasting. Hallmark features of PAD-associated skeletal muscle pathology include loss of skeletal muscle mass, reduced strength and physical performance, increased inflammation, fibrosis, and adipocyte infiltration. At the molecular level, skeletal muscle ischemia has also been associated with gene and microRNA (miRNA) dysregulation. Mesenchymal stromal cells (MSCs) have been shown to enhance muscle regeneration and improve muscle function in various skeletal muscle injuries. This study aimed to evaluate the effects of intramuscularly delivered human umbilical cord-derived MSCs (hUC-MSCs) on skeletal muscle ischemia. Herein, we report an hUC-MSC-mediated amelioration of ischemia-induced skeletal muscle atrophy and function via enhancement of myofiber regeneration, reduction of tissue inflammation, adipocyte accumulation, and tissue fibrosis. These changes were observed in the absence of cell-mediated enhancement of blood flow recovery as measured by laser Doppler imaging. Furthermore, reduced tissue fibrosis in the hUC-MSC-treated group was associated with upregulation of miR-1, miR-133a, and miR-29b and downregulation of targeted pro-fibrotic genes such as Col1a1 and Fn1. Our results support the use of hUC-MSCs as a novel approach to reduce fibrosis and promote skeletal muscle regeneration after ischemic injury in patients with PAD.
A quarter million Hmong Americans (Hmong) reside in the United States and 25% live in the Twin Cities metropolitan area. With a median age of 20.4 years old, this young community has a poverty rate of 26% in Minnesota and 27.4% nationally. Cervical cancer knowledge and prevention, such as awareness of HPV's effectiveness in reducing cancer risk, is low among Hmong women (19-50%) and men (38%), which may explain Hmong's high cervical cancer incidence rates (three times higher than other Asian Americans (AA) and four times higher than Non-Hispanic Whites). This problem is further aggravated by the rise of cervical cancer incidence and mortality rates among Hmong women. Clearly, multilevel strategies to increase HPV vaccination rates and reduce HPV-related cancers among Hmong are urgently needed. Yet Hmong women face structural and cultural barriers that limit their access to preventive health care. Language difficulties, poor health literacy, lack of time or transportation, visiting a doctor only when symptomatic or in pain and abstaining from gynecological visits due to embarrassment are some of these barriers. These barriers and beliefs must be carefully integrated into the design of any effective multilevel strategy to promote HPV vaccination uptake and completion. This study proposes to use a Community-Based Participatory Action Research (CBPAR) approach to develop and test the effectiveness of a theory-based culturally and cognitively appropriate mobile application (hAppy app) intervention that facilitate HPV vaccination completion among Hmong adolescents (11 to 17 years old) and their parents. Mobile health (mHealth) technology is a promising tool allowing for effective person-centered customization. The study's primary objective is to evaluate the effectiveness of hAppy app intervention in Hmong adolescents and their parents. 100 Hmong adolescents and their parents will be recruited and a single blind, two arm, randomized controlled trial will be conducted. Participants will be randomized by a 1:1 ratio to receive the hAppy app intervention (N=50) or usual care (UC, N=50) for a 9-month period.
PROBLEM TO BE SOLVED: To make a vital reaction such as a blood-sugar level measurable in non-invasion and simply by everyone. SOLUTION: A detector 20 applies an electromagnetic wave entering the interior of an organism to the organism of a user and detects the reflected or transmitted electromagnetic wave to thereby obtain the detection data of the user showing absorption spectrum of the electromagnetic wave due to subject material in the organism. The detection data is transmitted to a server 40 through the Internet by an Internet terminal device 30. A measured value calculating part 50 compares the detection data with a designated analytical curve to obtain a measured value of the user showing the concentration of the subject material in the organism. A data analyzing part 70 statistically processes the measured value of the user to obtain analysis data of the user with high accuracy.  According to the request of the user, the server 40 displays the analysis data or measured value of the user by the Internet terminal device 30.
PURPOSE: Every year around 70,000 people in Germany suffer from an abdominal incisional hernia that requires surgical treatment. Five years after reconstruction about 25% reoccur. Incisional hernias are usually closed with mesh using various reconstruction techniques, summarized here as standard reconstruction (SR). To improve hernia repair, we established a concept for biomechanically calculated reconstructions (BCR). In the BCR, two formulas enable customized patient care through standardized biomechanical measures. This study aims to compare the clinical outcomes of SR and BCR of incisional hernias after 1 year of follow-up based on the Herniamed registry.
METHODS: SR includes open retromuscular mesh augmented incisional hernia repair according to clinical guidelines. BCR determines the required strength (Critical Resistance to Impacts related to Pressure = CRIP) preoperatively depending on the hernia size. It supports the surgeon in reliably determining the Gained Resistance, based on the mesh-defect-area-ratio, further mesh and suture factors, and the tissue stability. To compare SR and BCR repair outcomes in incisional hernias at 1 year, propensity score matching was performed on 15 variables. Included were 301 patients with BCR surgery and 23,220 with standard repair.
RESULTS: BCR surgeries show a significant reduction in recurrences (1.7% vs. 5.2%, p = 0.0041), pain requiring treatment (4.1% vs. 12.0%, p = 0.001), and pain at rest (6.9% vs. 12.7%, p = 0.033) when comparing matched pairs. Complication rates, complication-related reoperations, and stress-related pain showed no systematic difference.
CONCLUSION: Biomechanically calculated repairs improve patient care. BCR shows a significant reduction in recurrence rates, pain at rest, and pain requiring treatment at 1-year follow-up compared to SR.
The women in the intervention group were explained how to perform the Reiki application, and the appropriate time for Reiki was planned. Pretest data were obtained by sending the data collection form, VAS-F and EPDS Google form link to women's phones via WhatsApp application.Then, according to Usui Reiki, researchers with Reiki Stage II and Reiki Master \& Teacher degrees applied Reiki to women for 30 minutes consecutively on the 13th, 14th, 20th and 21st postpartum days (in the second and third postpartum weeks). Before each Reiki application, a reminder message was sent to the women informing them that the application would begin, and they were asked to fill out the VAS-F and EPDS again on the 28th day (fourth week) and 56th day (eighth week) postpartum. During this process, women who did not fill out the scale forms were contacted via phone and SMS and were asked to fill out the forms, and those who did not fill out the forms were excluded from the study.
The invention relates to the technical field of biological engineering. At present, there is no effective vaccine for preventing hepatitis C virus (HCV) infection. The amino terminal of HCV envelope protein E2 has 27 amino acid residues with highest variability, known as hypervariable region 1(HVR1). The invention provides an HCV envelope protein E2 without HVR1, also provides an application of the HCV envelope protein E2 without HVR1 on HCV vaccines and HCV infection immunity diagnostic reagents. Animal immunization tests have discovered that HVR1 in 1-6 genotype HCV envelope protein E2 has substantial inhibition effect against immunogenicity of conservative neutralizing epitope in the envelope protein E2, the effectiveness of inducting broad spectrum neutralizing antibody by the E2 protein is significantly enhanced by deleting HVR1, the HCV envelope protein E2 with deleting HVR1 possibly can be used as an effective target antigen of HCV vaccines. The invention has proved that the HCV envelope protein E2 with deleting HVR1 has strong reaction with E2 antibody in serums of HCV infections and can be used as an immunity diagnostic antigen of HCV infections.